AstraZeneca Opens Access to 500,000 Genomes Through New Research Platforms
AstraZeneca is making genomic data from 500,000 UK Biobank participants available through two new open-access platforms. The MILTON and AZPheWAS portals provide machine learning tools and genetic association data that could accelerate therapeutic discovery. This move represents a significant step in the pharmaceutical industry’s growing embrace of open science principles.
In a major push toward open science, AstraZeneca has launched two platforms that provide researchers with unprecedented access to genetic data and analytical tools, according to recent announcements. The pharmaceutical giant’s new MILTON and AZPheWAS portals offer what industry observers are calling some of the most comprehensive open-access genomic resources currently available to the scientific community.